STANFORD, CA – April 24, 2024 – A protein primarily recognized for its vital role in stimulating red blood cell production, erythropoietin (EPO), has been unmasked in a groundbreaking study as a critical, yet surprising, suppressor of the immune system’s ability to combat cancer. Identified nearly 40 years ago for its hematologic functions, EPO’s newly discovered immunomodulatory role opens unprecedented avenues for cancer therapy, particularly for tumors currently resistant to conventional immunotherapies.
The pivotal research, published online today in the prestigious journal Science, reveals that blocking EPO’s activity can transform "cold," or immune-resistant, liver tumors in mice into "hot" tumors, teeming with an influx of potent cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy designed to further activate these immune cells, the results were astonishing: complete regression of established liver tumors in the vast majority of treated mice. These animals lived for the entire duration of the experiment, a stark contrast to control groups, which succumbed to their disease within a matter of weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," declared Edgar Engleman, MD, PhD, a distinguished professor of pathology and medicine at Stanford University, and the senior author of the study. His excitement was palpable as he added, "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
The research, led by basic life research scientist David Kung-Chun Chiu, PhD, promises to revolutionize treatment strategies for a wide array of cancers that have historically evaded effective immune responses, offering a beacon of hope for patients facing difficult prognoses.
A Hidden Suppressor: Unveiling EPO’s Immunomodulatory Role
For decades, erythropoietin has been celebrated as the master regulator of erythropoiesis – the process of red blood cell formation. Its discovery in the mid-20th century and subsequent clinical application as a therapeutic agent for anemia, particularly in patients with kidney disease or undergoing chemotherapy, marked a significant advance in medicine. However, EPO’s story in the context of cancer has always carried a perplexing shadow.
The Historical Enigma: EPO and Tumor Growth
The initial hints of EPO’s darker side in oncology emerged more than a decade ago. Clinical observations revealed a troubling paradox: while EPO effectively treated anemia in cancer patients, it also appeared to accelerate tumor growth. This alarming correlation was so pronounced that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-stimulating drugs, cautioning against their use in individuals with certain types of cancer. Simultaneously, researchers noted a clear link between patient prognosis and the natural levels of EPO and its receptor (EPOR) within tumors. Patients with higher levels often faced worse outcomes.
"Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman explained, reflecting on the historical data. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor."
This long-standing disconnect underscores the profound nature of the current discovery. The scientific community had largely compartmentalized EPO’s function, viewing it almost exclusively through the lens of hematology. The idea that a protein so intrinsically linked to blood production could simultaneously be a powerful immune checkpoint inhibitor was simply not on the radar, highlighting the intricate and often counterintuitive complexities of biological systems.
The Genesis of the Discovery: Chasing Immunotherapy Resistance
The journey to this groundbreaking insight began with Dr. Chiu’s meticulous work in developing and studying advanced genome editing techniques. His focus was on creating sophisticated mouse models of liver cancer that accurately recapitulated the specific mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. These models were crucial for dissecting the mechanisms of tumor development and, more importantly, understanding why some cancers respond to treatment while others remain stubbornly resistant. Tumor formation in these models was induced either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers.
A primary interest of the research team was to unravel the mysteries behind the varying efficacy of common immunotherapies, particularly those targeting the programmed cell death protein 1 (PD-1) pathway. Anti-PD-1 therapies, such as the commercially available Keytruda, operate by blocking the ability of cancer cells to "turn off" T cells – the immune system’s primary assassins. While these therapies have revolutionized the treatment landscape for certain cancers, including melanoma, Hodgkin’s lymphoma, and some lung cancers, a significant majority of tumors, encompassing many liver, pancreatic, colon, breast, and prostate cancers, remain largely unresponsive. These "cold" tumors present a major challenge in oncology, as they lack the necessary immune cell infiltration to mount an effective attack.
Consistent with observations in human liver cancers, the researchers found that certain combinations of genetic mutations in their mouse models led to the development of these "cold," immune-privileged liver tumors. These tumors were effectively ignored by the immune system and, consequently, showed no shrinkage when treated with anti-PD-1 therapy, simply because very few T cells were present within their microenvironment. In stark contrast, other genetic mutations resulted in "hot," or "inflamed," tumors, which were teeming with T cells and highly sensitive to anti-PD-1 treatment, leading to robust immune-mediated tumor destruction.
From "Cold" to "Hot": The Mechanism Unraveled
The crucial turning point came with an unexpected observation: the cold, immune-resistant tumors consistently displayed significantly elevated levels of EPO compared to their hot, immune-responsive counterparts. This discovery immediately piqued the researchers’ curiosity, prompting them to investigate the underlying cause and, more importantly, the functional implications of this disparity.
Hypoxia: The Driver of EPO Production in Tumors
The team quickly identified hypoxia – a condition of low oxygen – as the likely culprit behind the elevated EPO levels in cold tumors. Hypoxia is a common feature within the rapidly growing, often disorganized microenvironment of many solid tumors, particularly those with poor vascularization. Cancer cells, in response to this oxygen-deprived state, upregulate the production of various proteins, including those that, in turn, ramp up EPO production. The body’s natural physiological response to hypoxia is to produce more red blood cells to enhance oxygen delivery, and EPO is the key hormone orchestrating this process.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This statement encapsulates the paradigm shift brought about by the current research, highlighting how a widely accepted biological role can obscure other, equally critical functions.
Confirming the Correlation: Human Data Echoes Mouse Findings
To validate their observations beyond the mouse models, the researchers turned to existing human cancer databases. Their analysis confirmed a disturbing trend: elevated levels of EPO were indeed correlated with poorer survival rates in patients suffering from a diverse range of cancers, including those of the liver, kidney, breast, colon, and skin. This strong correlative evidence provided compelling support for the translatability of their findings from mice to humans.
Experimental Manipulation: Demonstrating Causality
With a strong correlation established, the team proceeded to conduct a series of elegant experiments designed to definitively prove a causal link between EPO and tumor immunity. They genetically tinkered with the ability of tumor cells to produce EPO in their mouse models, observing the remarkable consequences:
- Blocking EPO in Cold Tumors: When tumor cells that had previously led to the development of cold, immune-resistant tumors were genetically modified to be unable to produce EPO, a dramatic transformation occurred. These tumors, once immune-privileged, now became "hot," attracting an abundance of immune cells.
- Introducing EPO into Hot Tumors: Conversely, when hot tumors – which had previously been successfully eradicated by the immune system – were engineered to produce elevated levels of EPO, they thrived. The once-effective immune response was blunted, allowing the tumors to grow unchecked.
These reciprocal experiments provided unequivocal evidence that EPO was not merely a bystander but an active participant in shaping the tumor immune microenvironment.
The Cellular Mechanism: EPO, Macrophages, and T-Cell Exclusion
Further exhaustive research meticulously dissected the cellular and molecular mechanisms underlying EPO’s immunosuppressive role. The team discovered a precise sequence of events:
- EPO Secretion: In cold tumors, the tumor cells themselves produce and secrete EPO, often in response to the hypoxic conditions within the tumor.
- Macrophage Binding: This secreted EPO then travels to and binds with high affinity to its specific receptors (EPOR) located on the surface of nearby immune cells, specifically macrophages. Macrophages are a type of white blood cell that plays a dual role in the immune system, capable of both promoting and suppressing immune responses.
- Immunosuppressive Switch: Upon binding EPO, these macrophages undergo a critical phenotypic switch. They transform from a potentially pro-inflammatory, anti-tumor state into an immunosuppressive one.
- T-Cell Exclusion and Dampening: In their newly immunosuppressive role, these EPO-activated macrophages actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor core. Furthermore, they actively dampen the activity of any T cells that manage to gain entry, effectively neutralizing their anti-cancer function. This "crosstalk" between tumor cells and macrophages, mediated by EPO, creates an immune-deserted and immune-suppressed microenvironment – the hallmark of a cold tumor.
Synergistic Power: Combining EPO Blockade with Immunotherapy
The identification of EPO as a central player in immune evasion naturally led the researchers to investigate the therapeutic potential of blocking this pathway, particularly in combination with existing immunotherapies. Their experiments focused on the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. The results were nothing short of spectacular.
In control groups, mice with cold liver tumors that received no treatment, or only anti-PD-1 therapy, lived no longer than eight weeks after tumor induction. The anti-PD-1 therapy alone proved ineffective against these cold tumors, as predicted.
However, when mice with cold tumors were genetically modified such that their macrophages were unable to express the EPO receptor (thereby blocking EPO signaling), a significant improvement in survival was observed. Forty percent of these mice lived for 18 weeks after tumor induction, at which point the experiment was terminated, demonstrating a substantial anti-tumor effect from EPO blockade alone.
The true power of this discovery became evident when the EPO receptor blockade was combined with anti-PD-1 treatment. In this group, an astounding 100% of the animals lived for the entire duration of the experiment, achieving complete and durable tumor regression. This synergistic effect highlights a novel strategy to overcome resistance to current immunotherapies by fundamentally altering the tumor’s immune landscape.
"It’s simple," Dr. Engleman reiterated, emphasizing the clarity of the findings. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This statement encapsulates the profound clinical implications of the research, offering a direct path to making previously untreatable tumors responsive to existing powerful therapies.
Paving the Way for New Cancer Therapies
The implications of this discovery are far-reaching and hold immense promise for the future of cancer treatment. The finding that EPO acts as a powerful immune suppressor provides a novel therapeutic target for a broad spectrum of human cancers, particularly those that are currently resistant to anti-PD-1 and other checkpoint blockade immunotherapies.
Broad Applicability and Overcoming Resistance
The strong indications that EPO plays a similar role in many types of human cancers, supported by the human database analysis correlating elevated EPO levels with poor prognosis in liver, kidney, breast, colon, and skin cancers, suggest a wide applicability. Many of these cancers fall into the category of "cold" tumors, for which current immunotherapies offer limited benefit. By "heating up" these tumors through EPO blockade, this new strategy could unlock the full potential of existing immunotherapies, dramatically expanding their reach and impact.
Potential Therapeutic Strategies
Dr. Engleman and his colleagues are already actively engaged in designing new treatments targeting EPO signaling in human cancers. Two primary approaches are being considered:
- Non-specific EPO Targeting: One strategy involves broadly targeting the EPO protein itself. While this approach carries the potential side effect of causing anemia (given EPO’s role in red blood cell production), Dr. Engleman speculates that this might be an "acceptable trade-off" for an effective cancer therapy, especially for patients with aggressive, otherwise untreatable cancers.
- Selective Macrophage Receptor Blockade: A more refined and potentially less toxic approach would be to selectively block the EPO receptors specifically on the surfaces of macrophages within the tumor microenvironment. This targeted strategy would aim to disarm the immunosuppressive macrophages without interfering with EPO’s systemic red blood cell stimulating function, thereby mitigating the risk of anemia. This precision medicine approach holds significant promise for optimizing therapeutic benefit while minimizing adverse effects.
"I continue to be amazed by this finding," Dr. Engleman shared, reflecting on the depth of the discovery. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." His optimism is well-founded, given the robust preclinical data and the clear mechanistic understanding that has been elucidated.
Collaborations, Funding, and Future Outlook
This monumental research was a collaborative effort, benefiting from the contributions of researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. The study received substantial financial support from several grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), underscoring the importance and potential impact recognized by national funding bodies.
In the spirit of transparency, it is noted that Dr. Chiu is a co-founder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of ImmunEdge Inc. Furthermore, both Dr. Chiu and Dr. Engleman are Stanford-affiliated inventors named on a patent application (PCT/US2023/063997) titled "EPO receptor agonists and antagonists," highlighting the direct translational potential of their scientific endeavors.
The revelation of EPO’s critical role in cancer immune suppression marks a significant chapter in oncology. It not only solves a long-standing mystery surrounding EPO’s paradoxical effects on tumor growth but also offers a powerful new weapon in the arsenal against cancer. As research progresses towards human trials, the scientific community and patients alike will eagerly await the transformation of this groundbreaking discovery into life-saving therapies, bringing hope to those for whom current treatments fall short. The journey from a decades-old blood-booster to a potential game-changer in cancer immunotherapy underscores the endless capacity for scientific inquiry to reshape our understanding of disease and open new frontiers of healing.
About the Author
